Ranibizumab reduces foveal thickness

Article

Intraocular injections of ranibizumab significantly reduces foveal thickness and improves visual acuity (VA), thereby demonstrating that vascular endothelial growth factor (VEGF) is an important therapeutic target for diabetic macular oedema (DME), according to the results of a study published in the December 2006 issue of the American Journal of Ophthalmology.

Intraocular injections of ranibizumab significantly reduces foveal thickness and improves visual acuity (VA), thereby demonstrating that vascular endothelial growth factor (VEGF) is an important therapeutic target for diabetic macular oedema (DME), according to the results of a study published in the December 2006 issue of the American Journal of Ophthalmology.

Quan Dong Nguyen, MD, and colleagues from the Wilmer Eye Institute, USA, enrolled 10 patients with chronic DME to receive intraocular injections of 0.5 mg of ranibizumab at baseline and at one, two, four and six months. The primary outcome was change in foveal thickness between baseline and seven months, while the secondary outcome measures were changes from baseline in VA and macular volume.

The mean baseline values were, 503 µm for foveal thickness, 9.22 mm3 for macular volume and 28.1 letters read on an Early Treatment Diabetic Retinopathy Study (ETDRS) VA chart. At seven months follow-up, the mean foveal thicknoess was 257 µm, the macular volume was 7.47 mm3 and mean VA was 40.4 letters. Injections were well tolerated with no ocular or systemic adverse events reported.

The researchers believe that, as the injections reduced foveal thickness and improved VA in 10 patients with DME, VEGF is an important therapeutic target for DME. They suggest that a long-term trial is required to test whether the injections can provide long-term benefits to the patient.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.